Jake Galson is Alchemab’s Vice President of Technology where he leads the development and application of novel technologies for the company.
Prior to Alchemab, Jake was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Jake is also one of the pioneers of immune receptor repertoire sequencing, serving as a member of the AIRR community, and authoring numerous key publications in the area. He has also worked at The Oxford Vaccine Group, GSK Vaccines, and University of Zürich, applying this approach to further understand basic immunology, as well as in support of vaccine development, diagnostics, and antibody drug discovery.
Jake holds a PhD in Medical Sciences and a BA in Biological Sciences (First Class), both from the University of Oxford.